Editas Medicine, Inc.

LSE:0IFK Stock Report

Market Cap: US$185.0m

Editas Medicine Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0IFK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Aug 25SellUS$1,752Amy ParisonIndividual679US$2.58
31 Jul 25SellUS$12,757Linda BurklyIndividual5,121US$2.49
03 Jun 25SellUS$26,196Gilmore O’NeillIndividual15,192US$1.72
03 Jun 25SellUS$1,252Linda BurklyIndividual726US$1.72
03 Jun 25SellUS$769Amy ParisonIndividual446US$1.72
04 Mar 25SellUS$4,946Linda BurklyIndividual2,891US$1.71
04 Mar 25SellUS$28,452Gilmore O’NeillIndividual16,632US$1.71
04 Mar 25SellUS$7,030Erick LuceraIndividual4,109US$1.71
03 Dec 24SellUS$1,124Baisong MeiIndividual541US$2.08
03 Dec 24SellUS$3,361Gilmore O’NeillIndividual1,618US$2.08
04 Sep 24SellUS$5,325Gilmore O’NeillIndividual1,555US$3.42
04 Sep 24SellUS$1,774Baisong MeiIndividual518US$3.42

Insider Trading Volume

Insider Buying: 0IFK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0IFK?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders336,5500.402%
General Public38,820,04346.4%
Institutions44,556,26653.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 45.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.92%
The Vanguard Group, Inc.
7,466,254US$16.5m9.43%no data
7.99%
BlackRock, Inc.
6,690,680US$14.8m-8.45%no data
4.56%
UBS Asset Management AG
3,816,374US$8.4m67%no data
3.12%
Morgan Stanley, Investment Banking and Brokerage Investments
2,607,684US$5.8m106%no data
2.35%
Geode Capital Management, LLC
1,964,298US$4.3m1.06%no data
2.21%
State Street Global Advisors, Inc.
1,845,968US$4.1m-1.39%no data
1.92%
Dimensional Fund Advisors LP
1,608,477US$3.6m-25.5%no data
1.8%
Bank of America Corporation, Asset Management Arm
1,505,083US$3.3m258%no data
1.49%
Two Sigma Investments, LP
1,249,775US$2.8m-24.2%0.01%
1.45%
Two Sigma Advisers, LP
1,215,000US$2.7m-26.7%0.01%
1.23%
Renaissance Technologies LLC
1,032,965US$2.3m-28.8%no data
1.19%
AQR Capital Management, LLC
999,630US$2.2m-6.09%no data
0.83%
JP Morgan Asset Management
695,327US$1.5m3.68%no data
0.82%
Charles Schwab Investment Management, Inc.
684,896US$1.5m0%no data
0.78%
Northern Trust Global Investments
656,702US$1.5m-5.61%no data
0.7%
Susquehanna International Group, LLP, Asset Management Arm
585,035US$1.3m32.8%no data
0.63%
Kennedy Capital Management LLC
526,740US$1.2m-0.4%0.03%
0.57%
XTX Holdings Limited, Asset Management Arm
475,381US$1.1m353%0.05%
0.56%
J. Lamarck SIM S.p.A.
472,200US$1.0m0%1.23%
0.55%
D. E. Shaw & Co., L.P.
459,700US$1.0m156%no data
0.47%
Acadian Asset Management LLC
392,168US$866.7k-47.9%no data
0.44%
Jane Street Group, LLC, Asset Management Arm
370,791US$819.4k-65.5%no data
0.42%
Stifel Asset Management Corp.
354,787US$784.1k0%no data
0.34%
Millennium Management LLC
285,485US$630.9k-89.6%no data
0.34%
Goldman Sachs Asset Management, L.P.
285,366US$630.7k-55.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/11 06:13
End of Day Share Price 2025/08/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Editas Medicine, Inc. is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Joel BeattyBaird
Huidong WangBarclays